by 
Muscular dystrophy refers to a group of inherited genetic disorders that weaken the muscles over time. The diseases associated with muscular dystrophy primarily involve damage to muscles that help with movement. Currently, there is no definitive cure for muscular dystrophy and treatment primarily focuses on managing symptoms and improving quality of life. Advancements in gene therapy are providing promising therapeutic options for genetic muscular disorders.
The global muscular dystrophy treatment market is estimated to be valued at US$ 2.30 Billion in 2024 and is expected to exhibit a CAGR of 11% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the major trends in the muscular dystrophy treatment market is the development of gene therapies. Several biotechnology and pharmaceutical companies are investing in research and development for gene therapies targeting different forms of muscular dystrophy. For instance, Sarepta Therapeutics is developing multiple gene therapies such as SRP-9001 for Duchenne muscular dystrophy (DMD) which has received fast track designation from the U.S. FDA. Other companies such as Solid Biosciences are also developing gene therapies focused on DMD. Advancements in gene editing technologies such as CRISPR will further accelerate the development of novel gene therapies with potential to treat the underlying cause of genetic muscular dystrophies. Growing research activity and investment in this area signifies promising therapeutic options emerging in the market over the forecast period.
Porter’s Analysis
Threat of new entrants: Low as it requires high investment for R&D in drugs and treatment options. Significant clinical trial timelines and regulatory approvals are also required to enter this market.
Bargaining power of buyers: Moderate as few players operate in this niche segment. However, increasing treatment options raise competition.
Bargaining power of suppliers: Moderate as suppliers of raw material and manufacturing have established relationships with key players. Suppliers may still negotiate on pricing and contracts.
Threat of new substitutes: Low as no direct substitute currently exists for treatment of muscular dystrophy. Alternative treatment options act as complementary.
Competitive rivalry: High as major players invest heavily in R&D and product development. Strategic collaborations and M&As drive market competition to gain higher shares.
Key Takeaways
The global muscular dystrophy treatment market is expected to witness high growth.
Regional analysis: North America accounts for the largest share aided by increasing cases of Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD), favorable reimbursement policies, and rising awareness. Growing healthcare expenditure will further drive the Asia Pacific market in coming years.
Key players: Key players operating in the muscular dystrophy treatment market include F. Hoffmann-La Roche AG, PTC Therapeutics, Sarepta Therapeutics, and others. F. Hoffmann-La Roche AG holds a significant share with their portfolio of drugs to treat DMD. Sarepta Therapeutics is also a major player focused on exon-skipping therapies.
*Note:
- Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
